Integrated Biopharma Osake

Integrated Biopharma P/B

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Integrated Biopharma (INBP) 12.8.2026 päivämäärällä on 0,46. Edellisenä vuonna P/B (Hinta-kirjanpitoarvo-suhde) oli 0,48 — muutos −5,31 % (matalampi).

P/B

0,46

YoY

−5,31%

Viimeksi päivitetty:

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Integrated Biopharma on 2026 0,46 . P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Integrated Biopharma oli 2025 0,48 . Se laskee −5,31% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Integrated Biopharma Osakeanalyysi

Mitä Integrated Biopharma tekee? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Integrated Biopharma osakkeesta

Yhtiön Integrated Biopharma P/B (Hinta-kirjanpitoarvo-suhde) on 0,46 vuonna 2026.

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Integrated Biopharma muuttui arvosta 0,48 arvoon 0,46, mikä edustaa −5,31 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää P/B (Hinta-kirjanpitoarvo-suhde) Integrated Biopharma:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Hinta-kirjanpitoarvo-suhde vertaa yhtiön markkina-arvoa sen kirjanpitoarvoon. Matala P/B voi viitata aliarvostettuun osakkeeseen, kun taas korkea P/B voi osoittaa yliarvostusta tai vahvoja kasvuodotuksia.

P/B = Osakekurssi / Kirjanpitoarvo per osake

Arvioidakseen P/B (Hinta-kirjanpitoarvo-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja P/B (Hinta-kirjanpitoarvo-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata P/B (Hinta-kirjanpitoarvo-suhde):n Integrated Biopharma alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Integrated Biopharma

Kaikki tunnusluvut — Integrated Biopharma